www.addpr.com - Jul 01, 2011
- To launch in India under own brand name ‘Febramol IV’.
- World’s 1st company to stabilize the formulation with technological & formulation innovation.
- Product finalized after 3 years of susta.
Ahmedabad, July 1, 2011: Marck Biosciences Ltd., India’s leading manufacturer and marketer of sterile dosages and Blow-Fill-Seal (BFS) specialist, is now ready to launch world’s first ever Paracetamol IV in plastic pack manufactured using BFS technology in India. Marck will be contract manufacturing Paracetamol IV and will also launch it under its own brand name of ‘Febramol IV’ in India as well.
Speaking on the occasion, Mr Bhavesh Patel, MD, Marck Biosciences, said: “Due to our proven ability to innovate and create a pack that further reduced the potential for microbial infection during manufacture and F&D team’s dedicated efforts for 3 years, Marck has overcome the challenge of developing Paracetamol IV in Blow – Fill -Seal pack and launched this product for the 1st time in the world”.
Marck has invested approx US $3.5lacs to commercialize the production of Paracetamol IV and expects growth of approx US $1mn sales with Paracetamol IV in the first year of its launch.
The company has already pioneered the export of Paracetamol IV to West Africa, South East Asia and Middle East markets; and now is about to storm the Indian markets. Marck has received the approvals in Nigeria, Kenya, Benin, Mali, Vietnam and Yemen and is in the process of registering the innovative product in East Africa, CIS countries and Latin American countries.
“We would like to be the leader in all the markets, where we launch Paracetamol IV. Our product is stable, economical and availability will be assured. We are focussing on a two- pronged strategy of marketing Paracetamol IV under our own brand name and contract manufacturing to grow exponentially in the coming year. The response from other pharma companies is overwhelming and we are in the process of having an alliance internationally.” conveyed Mr. Patel.
Paracetamol IV is a ready to infuse dosage form of Paracetamol (in 10 mg/ml solution). It is indicated for the short-term treatment of moderate pain, especially following surgery and for the short-term treatment of fever urgently when other routes of administration are not possible. Paracetamol IV in plastic has lower freight costs and breakages and helps in more competitive pricing in comparison to glass bottles.Marck is the first company, which, after extensive R & D, has stabilized the formulation with technological & formulation innovation and launched it in plastic pack.
“The current size of Paracetamol IV market in India, is estimated around 2.5 mn bottles p.a. Since it is being launched for the first time in India the growth rate is expected to be in excess of 25% every year for the initial 3 yrs. Industry has enough capacity to keep itself busy and meet the growing demand.” said Mr. Patel.
Marck undertakes contract manufacturing of LVP and SVP for 48 of India’s Top 50 pharma companies. They include companies like Dr. Reddy’s, Torrent, Cadila, Themis, Zydus, Shreya, Glenmak, Ranbaxy, Sun Pharma, FDC, Macleods, Intas and Lupin.
Marck commenced operations in 1998 and today employs over 825 people. The manufacturing facility of Marck Biosciences, located in Kheda (Gujarat) and spread over an area of 25 acres, is benchmarked against global quality standards. The facility is certified by numerous international regulatory authorities including ANVISA (Brazil) & NPCB (Malaysia) – a PIC member country. The plant, equipment and systems have been designed to meet Current Good Manufacturing Practices (cGMP) & Quality Management System as laid down by many International Regulatory Authorities like MCC (South Africa), WHO (Geneva), MHRA (UK) & TGA (Australia). The Plant Quality Management System has been certified for ISO 9001 – 2000 & ISO 13485 (for medical devices).
Marck has filed a Draft Red Herring Prospectus for Public Issue of 1,30,00,000 equity shares of face value Rs. 10/- each by book building and has got SEBI approval. Marck plans to partly utilize the net proceeds of the IPO for setting up a sterile liquid manufacturing plant, for fluid therapy & formulations and the balance, for corporate needs and party for Issue cost. Marck intends to expand the operations by setting up a new high volume manufacturing facility for products with fill volume ranging from 100 ml to 1000 ml at an estimated cost of approx. Rs. 5533.04 lakhs. The facility is intended to be built to WHO cGMP specifications and will enhance Marck’s capacity by an additional 462lakhs bottles per annum.
- In the Press
